The sigmoid colon and bladder shielding in whole pelvic irradiation at prostate cancer (forward planned IMRT from Institute of Oncology Ljubljana)

Roach M 3rd, DeSilvio M, Lawton C, Uhl V, Machtay M, Seider MJ, et al. Phase III trial comparing whole-pelvic versus prostate-only radiotherapy and neoadjuvant versus adjuvant combined androgen suppression: Radiation Therapy Oncology Group 9413. J Clin Oncol 2003; 21: 1904-11.10.1200/JCO.2003.05.00412743142Search in Google Scholar

Jani A B, Su A, Milano MT. Intensity -modulated versus conventional pelvic radiotherapy for prostate cancer: analysis of acute toxicity. Urology 2006; 67: 147-51.10.1016/j.urology.2005.07.02116413351Search in Google Scholar

Peeters ST, Hoogeman MS, Heemsbergen WD, Hart AA, Koper PC, Lebesque JV. Rectal bleeding, fecal incontinence, and high stool frequency after conformal radiotherapy for prostate cancer: Normal tissue complication probability modeling. Int J Radiat Oncol Biol Phys 2006; 66: 11-9.10.1016/j.ijrobp.2006.03.03416757129Search in Google Scholar

Skala M, Rosewall T, Dawson L, Divanbeigi L, Lockwood G, Thomas C, et. al. Patient-assessed late toxicity rates and principal component analysis after image-guided radiation therapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 68: 690-8.10.1016/j.ijrobp.2006.12.06417379434Search in Google Scholar

Wawrovschek F, Vogt H, Wengenmair H, Weckermann D, Hamm M, Keil M, et al. Prostate lymphoscintigraphy and radioguided surgery for sentinel lymph node identification in prostate cancer. Technique and resultes of the first 350 cases. Urol Int 2003; 70: 303-10.Search in Google Scholar

De Meerleer GO, Villeirs GM, Vakaet L, Delrue LJ, De Neve WJ. The incidence of inclusion of the sigmoid colon and small bowel in the planning target volume in radiotherapy for prostate cancer. Strahlenther Oncol 2004, 9: 573-81.10.1007/s00066-004-1267-515378188Search in Google Scholar

Fonteyene V, De Neve W, Villeirs G, De Wagter C, De Meerleer G. Late radiotherapy-induced lower intestinal toxicity (RILIT) of intensity modulated radiotherapy for prostate cancer: the need for adapting the toxicity scales and the appearance of the sigmoid colon as co-responsible organ for lower intestinal toxicity. Radiother Oncol 2007; 84: 156-63.10.1016/j.radonc.2007.06.01317692976Search in Google Scholar

Pinkawa M, Fischendick K, Asadpour B, Gagel B, Piroth MD, Eble MJ. Low-grade toxicity after conformal radiation therapy for prostate cancer - impact of bladder volume. Int J Radiat Oncol Biol Phys 2006; 64: 835-41.10.1016/j.ijrobp.2005.09.00316289911Search in Google Scholar

Cheung MR, Tucker SL, Dong L, de Crevoisier R, Lee AK, Frank S, et al. Investigation of bladder dose and volume factors influencing late urinary toxicity after external beam radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2007; 67: 1059-65.10.1016/j.ijrobp.2006.10.042208196917241755Search in Google Scholar

Wang-Chesebro A, Xia P, Coleman J, Akazawa C, Roach M 3rd. Intensity-modulated radiotherapy improves lymph node coverage and dose to critical structures compared with three-dimensional conformal radiation therapy in clinically localized prostate cancer. Int J Radiat Oncol Biol Phys 2006; 66: 654-62.10.1016/j.ijrobp.2006.05.03717011444Search in Google Scholar